European Journal of Internal Medicine
Volume 20, Issue 1 , Pages 53-57 , January 2009

The efficacy of ranitidine bismuth citrate, amoxicillin and doxycycline or tetracycline regimens as a first line treatment for Helicobacter pylori eradication

  • Murat Akyildiz

      Affiliations

    • Ege University Medical School, Department of Gastroenterology, Bornova, Izmir, Turkey
    • Corresponding Author InformationCorresponding author. Atakent mah. Soyak Olimpiakent I. Etap D 4 No 43 Halkali, Istanbul, Turkey. Tel.: +90 533 240 21 04.
    • ,
  • Sinan Akay

      Affiliations

    • Ege University Medical School, Department of Gastroenterology, Bornova, Izmir, Turkey
    • ,
  • Ahmet Musoglu

      Affiliations

    • Ege University Medical School, Department of Gastroenterology, Bornova, Izmir, Turkey
    • ,
  • Muge Tuncyurek

      Affiliations

    • Ege University Medical School, Department of Pathology, Bornova, Izmir, Turkey
    • ,
  • Ahmet Aydin

      Affiliations

    • Ege University Medical School, Department of Gastroenterology, Bornova, Izmir, Turkey

Received 18 November 2007 ,Revised 14 March 2008 ,Accepted 27 April 2008.

References 

  1. Logan RP, Walker MM. ABC of the upper gastrointestinal tract: epidemiology and diagnosis of Helicobacter pylori infection. BMJ. 2001;323:920–922
  2. Sipponen P, Hyvarinen H. Role of Helicobacter pylori in the pathogenesis of gastritis, peptic ulcer and gastric cancer. Scand J Gastroenterol. 1993;196(suppl):3–6
  3. Stolte M, Eidt S. Healing gastric MALT lymphoma by eradication of H. pylori?. Lancet. 1993;342:568
  4. Malfertheiner P, Megraud F, O’Morain C, et al. Current concepts in the management of Helicobacter pylori infection— The Maastricht 2–2000 Consensus Report. Aliment Pharmacol Ther. 2002;16:167–180
  5. Gu Q, Xia HH, Wang JD, Wong WM, Chan AO, Lai KC, et al. Update on clarithromycin resistance in Helicobacter pylori in Hong Kong and its effect on clarithromycin-based triple therapy. Digestion. 2006;73:101–106
  6. Malfertheiner P, Megraud F, O'Morain C, Bazzoli F, El-Omar E, Graham D, et al. Current concepts in the management of Helicobacter pylori infection — The Maastricht III Consensus Report. Gut. 2007;56:772–781
  7. Megraud F. Update on therapeutic options for Helicobacter pylori-related diseases. Curr Infect Dis Rep. 2005;7:115–120
  8. Kadayifci A, Buyukhatipoglu H, Simsek İ, Koruk M. Turkiye'de H. pylori eradikasyonunda PPI, klaritromisin ve amoksisilin rejimlerinin etkinligi: bir meta-analiz. Turk J Gastroenterol. 2004;15(Suppl 1):A5
  9. Houben MH, van de Beek D, Hensen EF, Craen AJ, Rauws EA, Tytgat GN. A systematic review of Helicobacter pylori eradication therapy—the impact of antimicrobial resistance on eradication rates. Aliment Pharmacol Ther. 1999;13:1047–1055
  10. Midolo PD, Lambert JR, Ken TG. Ranitidine bismuth citrate can overcome in vitro antibiotic resistance in Helicobacter pylori. Gut. 1997;41(Suppl 1):A12
  11. Osato MS, Graham DY. Ranitidine bismuth citrate enhances clarithromycin activity against clinical isolates of H. pylori. Gastroenterology. 1997;112(suppl):A1057
  12. Megraud F, Roberts P, Williamson R. Ranitidine bismuth citrate can help to overcome Helicobacter pylori resistance to clarithromycin in vivo. Helicobacter. 2000;5:222–226
  13. Bago J, Halle ZB, Strinić D, Kućisec N, Jandrić D, Bevanda M, et al. The impact of primary antibiotic resistance on the efficacy of ranitidine bismuth citrate—vs. omeprazole-based one-week triple therapies in H. pylori eradication—a randomised controlled trial. Wien Klin Wochenschr. 2002;114:448–453
  14. Rinaldi V, Zullo A, De Francesco V, Hassan C, Winn S, Stoppino V, et al. Helicobacter pylori eradication with proton pump inhibitor-based triple therapies and re-treatment with ranitidine bismuth citrate-based triple therapy. Aliment Pharmacol Ther. 1999;1:163–168
  15. Tursi A, Brandimarte G, Giorgetti G, Modeo ME, Gigliobianco A. Efficacy and tolerability of ranitidine bismuth citrate plus amoxicillin and clarithromycin as first-or second-line therapy to cure Helicobacter pylori infection. Hepatogastroenterology. 2002;49:1006–1009
  16. Gisbert JP, Gisbert JL, Marcos S, Gravalos RG, Carpio D, Pajares JM. Seven-day ‘rescue’ therapy after Helicobacter pylori treatment failure: omeprazole, bismuth, tetracycline and metronidazole vs. ranitidine bismuth citrate, tetracycline and metronidazole. Aliment Pharmacol Ther. 1999;13:1311–1316
  17. Koksal AS, Parlak E, Filik L, Yolcu OF, Odemiş B, Ulker A, et al. Ranitidine bismuth citrate-based triple therapies as a second-line therapy for Helicobacter pylori in Turkish patients. J Gastroenterol Hepatol. 2005;20:637–642
  18. Chi CH, Lin CY, Sheu BS, Yang HB, Huang AH, Wu JJ. Quadruple therapy containing amoxicillin and tetracycline is an effective regimen to rescue failed triple therapy by overcoming the antimicrobial resistance of Helicobacter pylori. Aliment Pharmacol Ther. 2003;18:347–353
  19. Kwon DH, Kim JJ, Lee M, Yamaoka Y, Kato M, Osato MS, et al. Isolation and characterization of tetracycline-resistant clinical isolates of Helicobacter pylori. Antimicrob Agents Chemother. 2000;44:3203–3205
  20. Iovene MR, Romano M, Pilloni AP, Giordano B, Montella F, Caliendo S, et al. Prevalence of antimicrobial resistance in eighty clinical isolates of Helicobacter pylori. Chemotherapy. 1999;45:8–14
  21. Tankovic J, Lamarque D, Lascols C, Soussy CJ, Delchier JC. Clarithromycin resistance of Helicobacter pylori has a major impact on the efficacy of the omeprazole–amoxicillin–clarithromycin therapy. Pathol Biol. 2001;49:528–533
  22. Calvet X, Garcia N, Lopez T, Gisbert JP, Gene E, Roque M. A metaanalysis of short versus long therapy with a proton pump inhibitor, clarithromycin and either metronidazole or amoxycillin for treating Helicobacter pylori infection. Aliment Pharmacol Ther. 2000;14:603–609
  23. Aydin Ahmet, Büke Ç, Akiner C, Karasu Z, Demir A, Günhan C. Helicobacter pylori’nin klaritromisine duyarliligi azaliyor mu?. Turk J Gastroenterol. 1998;9(Suppl 1):A55
  24. Onder GF, Aydin A, Akarca US, Tekin F, Ozutemiz O, Ilter T. High Helicobacter pylori resistance rate to clarithromycin in Turkey. J Clin Gastroenterol. 2007;41:747–750
  25. Aydin A, Onder GF, Akarca US, Tekin F, Tuncyurek M, Ilter T. Comparison of one and two-week pantoprazole-based triple therapies in clarithromycin sensitive and resistant cases. Eur J Intern Med. 2007;18:496–500
  26. Georgopoulos SD, Ladas SD, Karatapanis S, Triantafyllou K, Spiliadi C, Mentis , et al. Effectiveness of two quadruple, tetracycline- or clarithromycin-containing, second-line, Helicobacter pylori eradication therapies. Aliment Pharmacol Ther. 2002;16:569–575
  27. Graham DY, Lew GM, Ramirez FC, Genta RM, Klein PD, Malaty HM. Short report: a non-metronidazole triple therapy for eradication of Helicobacter pylori infection-tetracycline, amoxicillin, bismuth. Aliment Pharmacol Ther. 1993;1:111–113
  28. Perri F, Festa V, Merla A, Quitadamo M, Clemente R, Andriulli A. Amoxicillin/tetracycline combinations are inadequate as alternative therapies for Helicobacter pylori infection. Helicobacter. 2002;7:99–104
  29. Cammarota G, Martino A, Pirozzi G, Cianci R, Branca G, Nista EC, et al. High efficacy of 1-week doxycycline- and amoxicillin-based quadruple regimen in a culture-guided, third-line treatment approach for Helicobacter pylori infection. Aliment Pharmacol Ther. 2004;19:789–795
  30. Cudia B, Romano B, Gioe FP, Barbera N, LoGerfo D, Montalto R, et al. ‘Rescue’ therapy including ranitidine bismuth citrate+minocicline+amoxicillin for eradication of Helicobacter pylori infection in previous H.P. treatment failure. Gut. 1997;41(Suppl 1):A103
  31. Gomollon F, Sicilia B, Ducons JA, Sierra E, Revillo MJ, Ferrero M. Third line treatment for Helicobacter pylori: a prospective, culture-guided study in peptic ulcer patients. Aliment Pharmacol Ther. 2000;14:1335–1338
  32. Cheon JH, Kim SG, Kim JM, Kim N, Lee DH, Kim JS, et al. Combinations containing amoxicillin–clavulanate and tetracycline are inappropriate for Helicobacter pylori eradication despite high in vitro susceptibility. J Gastroenterol Hepatol. 2006;21:590–595

PII: S0953-6205(08)00133-7

doi: 10.1016/j.ejim.2008.04.003

European Journal of Internal Medicine
Volume 20, Issue 1 , Pages 53-57 , January 2009

Article Tools